AI assistant
AMGEN INC — Director's Dealing 2019
Mar 9, 2019
29819_dirs_2019-03-08_1b8a917c-e0ab-4d45-8591-adbc4b929ca6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2019-03-06
Reporting Person: Meline David W (EVP & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-03-06 | Common Stock | A | 16086 | — | Acquired | 62746 | Direct |
Footnotes
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 533 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.